CHP PhD Completion Seminar - Marie-Anne Boujaoude
Share via
Title: Advancing New Methods in Addressing Equity in Health Technology Assessment - An Application to Australia
Webinar link: https://go.unimelb.edu.au/p33p
Webinar ID: 88184646934. Webinar Passcode: 352711
Location: Lecture Theatre B103, 207 Bouverie Street, Carlton
Supervisors: A/Prof Natalie Carvalho, Economics of Global Health and Infectious Diseases Unit, Melbourne Health Economics, Centre for Health Policy, Melbourne School of Population and Global Health, The University of Melbourne; Prof Kim Dalziel, Child Health Economics Unit, Melbourne Health Economics, Centre for Health Policy, Melbourne School of Population and Global Health, The University of Melbourne; Prof Nancy Devlin, Child Health Economics Unit, Melbourne Health Economics, Centre for Health Policy, Melbourne School of Population and Global Health, The University of Melbourne
Bio: Marie-Anne Boujaoude is a PhD student with the Economics of Global Health and Infectious Diseases Unit, Melbourne Health Economics. Her research focuses on advancing methods for gauging public concern for reducing inequality in health and for the implementation of equity-informative methods of health economic evaluations. She co-founded the Equity in Asia Pacific Health Technology Assessment (EquitAP-HTA) network with A/Prof Isaranuwatchai from HITAP (Thailand) to promote equity-informed decision-making and strengthen regional collaboration and methodological capacity in equity-informative economic evaluations.
Abstract: Equity is increasingly recognised as a key consideration in health technology assessment (HTA), yet equity-informative methods are not widely used in standard HTA practice. This PhD advances approaches for incorporating equity into HTA in the Australian context. It begins by examining how equity is currently reflected in national vaccine recommendations, then elicits societal preferences for reducing health inequalities, and demonstrates the application of an equity-informative economic evaluation, distributional cost-effectiveness analysis (DCEA), using pneumococcal vaccination as a case study.